GNC

The system's trajectory paints a cautionary picture: total franchise locations dropped from 750 in 2023 to 703 in 2024—a 6% contraction—amid just 3 projected new units, 22 terminations, 36 non-renewals, and 23 transfers. Corporate-owned stores number 1,437, dwarfing franchises, which hints at a top-heavy model where the parent (Harbin Pharmaceutical Group) prioritizes control over expansion. FDD Item 19 reveals average gross revenue of $475,925 and median $443,685 per unit, but with only 14 SBA loans averaging $158,657, financing access appears limited, underscoring subdued franchisee momentum.

Economics start accessibly with a $20,000 franchise fee, but ongoing costs bite: 6% royalty, 3% brand/ad fund, plus $342-$383 monthly tech/network fees (network $233, tech maintenance $75-$100, CC processing $16, Wi-Fi $18, optional cellular $16). No full investment range in core data, yet these fees on sub-$500K sales leave thin margins before expenses—especially in a contracting system. Red flags abound: arbitrations with international franchisees over breaches, wrongful terminations, and unauthorized conversions; plus confirmed bankruptcy history. For investors eyeing health retail, GNC's data screams 'proceed with caution'—proven brand, decent top-line, but shrinking footprint and legal baggage erode the appeal.